In fact, PAX5 hypermethylation has been described in many non-hematological cancers, particularly where PAX5 is characterized as a tumor suppressor (e.g., hepatocellular carcinoma [100], ovarian carcinoma [107]; head and neck cancer [76], gastric cancer [105], lung and breast cancer malignancies [108,148]). Here, PAX5 is linked to hematopoietic and lymphoid cell neoplasm.